Clinical Data Viridian reports positive results from elegrobart phase 3 trial PharmaTimesCompany says treatment shows strong efficacy and convenient dosing profileClinical DataRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) PharmaTimes Company says treatment shows strong efficacy and convenient dosing profile Clinical DataRead full story Post navigation Previous: ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2DNext: FDA approves new high dose Spinraza regimen for SMA Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026